Literature DB >> 27050845

Myotonic dystrophy type 1: frequency of ophthalmologic findings.

Karin Suzete Ikeda1, Cristina Iwabe-Marchese2, Marcondes Cavalcante França2, Anamarli Nucci2, Keila Monteiro de Carvalho1.   

Abstract

The purpose of the study was to evaluate the frequency of ophthalmologic abnormalities in a cohort of myotonic dystrophy type 1 (DM1) patients and to correlate them with motor function. We reviewed the pathophysiology of cataract and low intraocular pressure (IOP). Method Patients were included after clinical and laboratory diagnosis and after signed informed consent. They were evaluated by Motor Function Measure scale, Portuguese version (MFM-P) and ophthalmic protocol. Results We evaluated 42 patients aged 17 to 64 years (mean 40.7 ± 12.5), 22 of which were men. IOP (n = 41) was reduced in all but one. We found cataract or positivity for surgery in 38 (90.48%) and ptosis in 23 (54.76%). These signs but not IOP were significantly correlated with severity of motor dysfunction. Abnormalities in ocular motility and stereopsis were observed. Conclusion Cataract and ptosis are frequent in DM1 and associated to motor dysfunction. Reduced IOP is also common, but appears not to be related with motor impairment.

Entities:  

Mesh:

Year:  2016        PMID: 27050845     DOI: 10.1590/0004-282X20150218

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  3 in total

1.  Efficacy and safety of ropivacaine HCl in peribulbar anaesthesia for cataract surgery in patients with myotonic dystrophy type 1.

Authors:  Alberto Palladino; Maddalena De Bernardo; Marianna Scutifero; Michele Lanza; Silvio De Querquis; Nicola Rosa; Luisa Politano
Journal:  Acta Myol       Date:  2020-06-01

2.  Stellate nonhereditary idiopathic foveomacular retinoschisis resolution after vitreomacular adhesion release.

Authors:  Thiago Machado Nogueira; Daniel de Souza Costa; Jordan Isenberg; Flavio A Rezende
Journal:  Am J Ophthalmol Case Rep       Date:  2021-06-19

Review 3.  Targeting Myotonic Dystrophy Type 1 with Metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Ander Matheu; Adolfo López de Munain
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.